Drug development for cystic fibrosis-Reference-Cited by-同舟云学术

Drug development for cystic fibrosis

Published:2021-01-12 Issue:S1 Volume:56 Page:
ISSN:8755-6863
Container-title:Pediatric Pulmonology
language:en
Short-container-title:Pediatric Pulmonology

Author:

Sanders Don B.¹^ORCID,Chmiel James F.¹^ORCID

Affiliation:

1. Division of Pediatric Pulmonology, Allergy and Sleep Medicine, Department of Pediatrics, Indiana University School of Medicine Riley Hospital for Children at IU Health Indianapolis Indiana USA

Funder

Cystic Fibrosis Foundation

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ppul.25075

Reference63 articles.

1. Accelerating drug discovery

2. Clinical development success rates for investigational drugs

3. Innovation in the pharmaceutical industry: New estimates of R&D costs

4. MedicineNet. Drug approvals—from invention to market… A 12‐year trip. 1999.https://www.medicinenet.com/script/main/art.asp?articlekey=9877. Accessed August 24 2020.

5. The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain;European Respiratory Journal;2024-02-01

2. Traits, trends and hits of orphan drug designations in cystic fibrosis;Journal of Cystic Fibrosis;2023-09

3. ABC transporters: human disease and pharmacotherapeutic potential;Trends in Molecular Medicine;2023-02

4. Inflammation and Infection in Cystic Fibrosis: Update for the Clinician;Children;2022-12-02

5. Novel treatments for autism spectrum disorder based on genomics and systems biology;Pharmacology & Therapeutics;2022-02